These antitumor properties are also demonstrated by a number of sartans, selective Ang II AT1-receptor antagonists [94-101], further reinforcing that blockade of AT1R could be an effective anticancer strategy, not only because these drugs target cancer cells, but also endothelial cells at the tumor and stroma. The gene discussed is AGTR1; the disease is cancer.